PuSH - Publication Server of Helmholtz Zentrum München

37 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Jall, S. et al.: Pirt deficiency has subtle female-specific effects on energy and glucose metabolism in mice. Mol. Metab. 23, 75-81 (2019)
2.
Khajavi, N.* et al.: Tri-agonist-induced PLC activation is associated with robust insulin secretion from murine islets. Naunyn-Schmiedebergs Arch. Pharmakol. 392, S35-S35 (2019)
3.
Mroz, P.A.* et al.: Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol. Metab. 20, 51-62 (2019)
4.
Clemmensen, C. et al.: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes. Nat. Commun. 9:4304 (2018)
5.
Clemmensen, C. et al.: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes (vol 9, 4304, 2018). Nat. Commun. 9:4975 (2018)
6.
Khajavi, N.* et al.: An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation. Cell. Signal. 51, 13-22 (2018)
7.
Müller, T.D. ; Clemmensen, C. ; Finan, B. ; DiMarchi, R.D.* & Tschöp, M.H.: Anti-obesity therapy: From rainbow pills to polyagonists. Pharmacol. Rev. 70, 712-746 (2018)
8.
Renner, S.* et al.: Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs. Mol. Metab., accepted (2018)
9.
Fischer, K. et al.: Alternatively activated macrophages do not synthesize catecholamines or contribute to adipose tissue adaptive thermogenesis. Nat. Med. 23, 623-630 (2017)
10.
Jall, S. et al.: Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol. Metab. 6, 440-446 (2017)
11.
Müller, T.D. ; Finan, B. ; Clemmensen, C. ; DiMarchi, R.D. & Tschöp, M.H.: The new biology and pharmacology of glucagon. Physiol. Rev. 97, 721-766 (2017)
12.
Quarta, C. et al.: Molecular integration of incretin and glucocorticoid action reverses immunometabolic dysfunction and obesity. Cell Metab. 26, 620-632.e6 (2017)
13.
Clemmensen, C. ; Müller, T.D. ; Finan, B. ; Tschöp, M.H. & DiMarchi, R.*: Current and emerging treatment options in diabetes care. Handb. Exp. Pharmacol. 233, 437-459 (2016)
14.
de Angelis, M. et al.: Determination of thyroid hormones in mouse tissues by isotope-dilution microflow liquid chromatography-mass spectrometry method. J. Chromatogr. B 1033-1034, 413-420 (2016)
15.
Finan, B. ; Müller, T.D. ; Clemmensen, C. ; Perez-Tilve, D.* & Tschöp, M.H.: Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol. Med. 22, 359-376 (2016)
16.
Finan, B. et al.: Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic Impact for metabolic disease. Cell 167, 843-857.e14 (2016)
17.
Kabra, D.G. et al.: Hypothalamic leptin action is mediated by histone deacetylase 5. Nat. Commun. 7:10782 (2016)
18.
Sánchez-Garrido, M.A. et al.: Fibroblast activation protein (FAP) as a novel metabolic target. Mol. Metab. 5, 1015-24 (2016)
19.
Tschöp, M.H. et al.: Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 24, 51-62 (2016)
20.
Vogel, H.* et al.: GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight. Neuropharmacol. 110, 396-406 (2016)